AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18466184 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental PE program (n=77)
Number of subjects: 152
Study 18466184 — intervention group
Group type: COMPARATOR
Intervention: Traditional PE program (n=75)
Number of subjects: 152
Study 17334939 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based case management intervention
Number of subjects: 162
Study 17334939 — intervention group
Group type: COMPARATOR
Intervention: Passive referral
Number of subjects: 162
Study 15082350 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 51
Study 15082350 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Terlipressin (crossover from placebo)
Number of subjects: 51
Study 15082350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11437769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 20
Study 9667681 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (200 units kg(‐1) day(‐1) plus oral iron supplements 325 mg p.o. t.i.d.)
Number of subjects: 48
Study 9667681 — intervention group
Group type: COMPARATOR
Intervention: Control (no r‐HuEPO treatment)
Number of subjects: 48
Study 9667681 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 48
Study 9667681 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 8065869 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk criteria for serious bacterial infection (SBI)
Number of subjects: 1057
Study 2646360 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (glypressin)
Number of subjects: 60
Study 2646360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31010425 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary self-management intervention
Number of subjects: 281
Study 28283830 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of fluoroquinolone treatment
Number of subjects: 100
Study 28283830 — intervention group
Group type: COMPARATOR
Intervention: 10 days of fluoroquinolone treatment
Number of subjects: 100
Study 26228536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavior Therapy (ABBT)
Number of subjects: 81
Study 26228536 — intervention group
Group type: COMPARATOR
Intervention: Applied Relaxation (AR)
Number of subjects: 81
Study 26228536 — intervention group
Group type: COMPARATOR
Intervention: Both ABBT and AR
Number of subjects: 81
Study 23773306 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal verbal scaffolding
Number of subjects: 131
Study 21982411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg
Number of subjects: 22
Study 21982411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg plus Ezetimibe 10 mg
Number of subjects: 22
Study 21982411 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg
Number of subjects: 22
Study 21982411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib + Ezetimibe
Number of subjects: 22
Study 18058165 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 1048
Study 18058165 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 1048
Study 18058165 — intervention group
Group type: COMPARATOR
Intervention: Overall analysis of original articles
Number of subjects: 1048
Study 18058165 — intervention group
Group type: COMPARATOR
Intervention: Quality of reporting
Number of subjects: 1048
Study 16827019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation of the maxilla (Group A)
Number of subjects: 28
Study 16827019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation of the mandible (Group B)
Number of subjects: 28
Study 12957566 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 72
Study 12957566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 11029965 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg Cu‐glycine chelate
Number of subjects: 24
Study 11029965 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg Cu‐glycine chelate
Number of subjects: 24
Study 11029965 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg CuSO4
Number of subjects: 24
Study 8851594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime as intermittent bolus (IB) 2 g i.v. every 8 h (q8h) for 2 days
Number of subjects: 12
Study 8851594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime as continuous infusion (CI) 3 g continuous infusion over 24 h for 2 days
Number of subjects: 12
Study 8851594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (both regimens) in presence of tobramycin (4 to 7 mg/kg i.v. q24h)
Number of subjects: 12
Study 1319982 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy + alpha interferon
Number of subjects: 20
Study 1319982 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 20
Study 6703681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide (1 g every 12 h)
Number of subjects: 32
Study 6703681 — intervention group
Group type: COMPARATOR
Intervention: Cephapirin (2 g every 4 h)
Number of subjects: 32
Study 6703681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide
Number of subjects: 32
Study 6703681 — intervention group
Group type: COMPARATOR
Intervention: Cephapirin
Number of subjects: 32
Study 30014664 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 120
Study 30014664 — intervention group
Group type: COMPARATOR
Intervention: Tramadol hydrochloride tablets
Number of subjects: 120
Study 26968285 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intramasseteric injection of 2ml of 8mg/2ml dexamethasone
Number of subjects: 20
Study 26968285 — intervention group
Group type: COMPARATOR
Intervention: Control group received 2ml of sterile saline solution
Number of subjects: 20
Study 25666690 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy plus TrP‐DN (n = 10)
Number of subjects: 20
Study 25666690 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (n = 10)
Number of subjects: 20
Study 23073338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with inactivity on fundus fluorescein angiography at month 3
Number of subjects: 0
Study 23073338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with qualitative OCT inactivity at month 5
Number of subjects: 0
Study 23073338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with qualitative OCT inactivity at month 8
Number of subjects: 0
Study 23073338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with leakage on OCT
Number of subjects: 0
Study 23073338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with inactivity on fundus fluorescein angiography at months 3 and 5
Number of subjects: 0
Study 20695184 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bowel preparation procedure (Group B)
Number of subjects: 100
Study 20695184 — intervention group
Group type: COMPARATOR
Intervention: No preoperative bowel preparation (Group A)
Number of subjects: 100
Study 18204341 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming stimulation (twenty 5-second, 6-Hz trains)
Number of subjects: 60
Study 18204341 — intervention group
Group type: COMPARATOR
Intervention: Sham-priming (equivalent to priming stimulation)
Number of subjects: 60
Study 16364548 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation (45‐50 degrees C)
Number of subjects: 0
Study 16364548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of pain questionnaire (FPQ)
Number of subjects: 0
Study 16364548 — intervention group
Group type: COMPARATOR
Intervention: Generalized anxiety (indexed by STAI‐T scores)
Number of subjects: 0
Study 16364548 — intervention group
Group type: COMPARATOR
Intervention: Neutral thermal stimulation (38 degrees C)
Number of subjects: 0
Study 14653281 — intervention group
Group type: EXPERIMENTAL
Intervention: Duceram LFC‐Degussa
Number of subjects: 60
Study 14653281 — intervention group
Group type: EXPERIMENTAL
Intervention: Solidex‐Shofu
Number of subjects: 60
Study 14653281 — intervention group
Group type: EXPERIMENTAL
Intervention: Artglass‐Heraeus Kulzer
Number of subjects: 60
Study 14653281 — intervention group
Group type: EXPERIMENTAL
Intervention: Targis‐Ivoclar
Number of subjects: 60
Study 11221150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 42
Study 11221150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) and Fluvoxamine (FVX)
Number of subjects: 42
Study 11221150 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (FVX) alone
Number of subjects: 42
Study 9095122 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) intravenous up to 30 ng/kg/min for 72 hours after surgery
Number of subjects: 45
Study 9095122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8229122 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg/d of megestrol acetate
Number of subjects: 131
Study 8229122 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/d of megestrol acetate
Number of subjects: 131
Study 8229122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,600 mg/d of megestrol acetate
Number of subjects: 131
Study 3782653 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-modified ragweed extract administered via weekly injections
Number of subjects: 50
Study 3782653 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-modified ragweed extract administered via daily injections until adverse reaction, then switched to weekly schedule
Number of subjects: 50
Study 29128682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated eyelid cleanser (TheraTears® SteriLid®)
Number of subjects: 43
Study 29128682 — intervention group
Group type: COMPARATOR
Intervention: Diluted baby shampoo (Johnson's® No More Tears®)
Number of subjects: 43
Study 27342141 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive enrollment in quitline
Number of subjects: 1980
Study 27342141 — intervention group
Group type: COMPARATOR
Intervention: Provider suggestion to use quitline
Number of subjects: 1980
Study 27342141 — intervention group
Group type: COMPARATOR
Intervention: No enrollment or suggestion
Number of subjects: 1980
Study 27342141 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline users (all types)
Number of subjects: 1980
Study 24022270 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC HYP) 150 mg or 300 mg, administered subcutaneously every four weeks for 52 weeks
Number of subjects: 178
Study 24022270 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered subcutaneously every four weeks for 52 weeks
Number of subjects: 178
Study 24022270 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC HYP)
Number of subjects: 178
Study 24022270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 24211753 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline KEEP screening for CKD
Number of subjects: 434
Study 24211753 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up KEEP screening for CKD
Number of subjects: 434
Study 24211753 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up KEEP for patients who tested positive for CKD at baseline
Number of subjects: 434
Study 21383045 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3207 200 mg
Number of subjects: 547
Study 21383045 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3207 100 mg
Number of subjects: 547
Study 21383045 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-3207 10 mg
Number of subjects: 547
Study 21383045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 19123307 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + laser irradiation
Number of subjects: 13
Study 19123307 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (control group)
Number of subjects: 13
Study 16796898 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided pin axial position fluoroscopy
Number of subjects: 80
Study 16796898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicle axial fluoroscopy
Number of subjects: 80
Study 16796898 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroposterior fluoroscopy
Number of subjects: 80
Study 14564253 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional remifentanil (0.2 microg kg(‐1) min(‐1) over 5 minutes)
Number of subjects: 48
Study 14564253 — intervention group
Group type: COMPARATOR
Intervention: Postincisional remifentanil (0.5 microg kg(‐1) min(‐1) for 50 minutes, then 0.25 microg kg(‐1) min(‐1))
Number of subjects: 48
Study 11082723 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with concomitant chemotherapy (arm B)
Number of subjects: 226
Study 11082723 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (arm A)
Number of subjects: 226
Study 8931343 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50
Study 8931343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1410157 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine delivery cigarettes
Number of subjects: 39
Study 1410157 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium nicotine delivery cigarettes
Number of subjects: 39
Study 1410157 — intervention group
Group type: COMPARATOR
Intervention: Denicotinised cigarette
Number of subjects: 39
Study 1410157 — intervention group
Group type: COMPARATOR
Intervention: No-smoking control condition
Number of subjects: 39
Study 3956056 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 6
Study 3956056 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 6
Study 3956056 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 6
Study 3956056 — intervention group
Group type: COMPARATOR
Intervention: All three regimens (Enprofylline, Theophylline, Saline)
Number of subjects: 6
Study 31958991 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling video intervention
Number of subjects: 104
Study 31958991 — intervention group
Group type: COMPARATOR
Intervention: Information-based written material (comparison group)
Number of subjects: 104
Study 30220407 — intervention group
Group type: EXPERIMENTAL
Intervention: PAXG (cisplatin 30 mg/m2, nab-paclitaxel 150 mg/m2, gemcitabine 800 mg/m2 on days 1 and 15, and oral capecitabine 1250 mg/m2 on days 1-28 every 4 weeks)
Number of subjects: 83
Study 30220407 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks)
Number of subjects: 83
Study 30220407 — intervention group
Group type: EXPERIMENTAL
Intervention: PAXG
Number of subjects: 83
Study 30220407 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 83
Study 27681755 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-VMAT 55 Gy in 25 consecutive 2.2-Gy fractions
Number of subjects: 70
Study 27681755 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-VMAT 60 Gy in 2.4-Gy fractions
Number of subjects: 70
Study 27681755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dose levels of SIB-VMAT
Number of subjects: 70
Study 25439206 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CSF
Number of subjects: 24
Study 25439206 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser‐aided CSF
Number of subjects: 24
Study 25439206 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 24
Study 25439206 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 25439206 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF groups
Number of subjects: 24
Study 22992240 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to Breathlessness Support Service (BSS) in addition to standard care
Number of subjects: 0
Study 22992240 — intervention group
Group type: COMPARATOR
Intervention: Standard best practice and access to BSS after a waiting time of six weeks
Number of subjects: 0
Study 22992240 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to BSS in addition to standard care
Number of subjects: 0
Study 21174285 — intervention group
Group type: EXPERIMENTAL
Intervention: PCVDP (active clinics)
Number of subjects: 4315
Study 21174285 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-PCVDP clinics)
Number of subjects: 4315
Study 18575220 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel
Number of subjects: 172
Study 18575220 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene 0.1% gel
Number of subjects: 172
Study 19298572 — intervention group
Group type: EXPERIMENTAL
Intervention: FPANS 200 microg bd
Number of subjects: 0
Study 19298572 — intervention group
Group type: EXPERIMENTAL
Intervention: FPANS 200 microg od
Number of subjects: 0
Study 19298572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15036850 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine Positioning
Number of subjects: 28
Study 15036850 — intervention group
Group type: COMPARATOR
Intervention: Prone Positioning
Number of subjects: 28
Study 11494543 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged IFN therapy
Number of subjects: 0
Study 11494543 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta therapy twice a day
Number of subjects: 0
Study 11494543 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta therapy daily for 24 weeks
Number of subjects: 0
Study 11494543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of IFN-alpha and IFN-beta
Number of subjects: 0
Study 11494543 — intervention group
Group type: COMPARATOR
Intervention: Standard IFN therapy
Number of subjects: 0
Study 9593129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir (300 mg twice a day for 5 days)
Number of subjects: 558
Study 9593129 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (250 mg four times a day for 10 days)
Number of subjects: 558
Study 9593129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 558
Study 9593129 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 558
Study 7923322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 1809
Study 3170403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic negative pressure changes at the oropharynx (OP) simulating inspiratory resistive loading
Number of subjects: 11
Study 3170403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic negative pressure changes at the oropharynx (OP) simulating expiratory resistive unloading
Number of subjects: 11
Study 3170403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic negative pressure changes at the oropharynx (OP) simulating elastic loading
Number of subjects: 11
Study 3170403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic positive pressure changes at the oropharynx (OP) simulating inspiratory resistive unloading
Number of subjects: 11
Study 3170403 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic positive pressure changes at the oropharynx (OP) simulating expiratory resistive loading
Number of subjects: 11
Study 3170403 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading via tracheostomy with similar pressures
Number of subjects: 11
Study 31589545 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with Cochlear Implants (CCIs)
Number of subjects: 0
Study 31589545 — intervention group
Group type: EXPERIMENTAL
Intervention: Postlingually deaf adults with Cochlear Implants (CIs)
Number of subjects: 0
Study 31589545 — intervention group
Group type: COMPARATOR
Intervention: Normal Hearing (NH) listeners
Number of subjects: 0
Study 29850937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg (pre-hemodialysis)
Number of subjects: 27
Study 29850937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg (post-hemodialysis)
Number of subjects: 27
Study 29850937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg (healthy subjects)
Number of subjects: 27
Study 29850937 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C124910XX (pre-hemodialysis)
Number of subjects: 27
Study 29850937 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C124910XX (post-hemodialysis)
Number of subjects: 27
Study 29850937 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C124910XX (healthy subjects)
Number of subjects: 27
Study 29850937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (all treatments)
Number of subjects: 27
Study 27362956 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI group (Q4)
Number of subjects: 38810
Study 27362956 — intervention group
Group type: EXPERIMENTAL
Intervention: High WC group
Number of subjects: 38810
Study 27362956 — intervention group
Group type: COMPARATOR
Intervention: Low BMI group (Q1)
Number of subjects: 38810
Study 25230867 — intervention group
Group type: EXPERIMENTAL
Intervention: HVHF treatment (18 hours per day on days 1, 3, 5, 7)
Number of subjects: 163
Study 25230867 — intervention group
Group type: EXPERIMENTAL
Intervention: PiCCO + HVHF treatment
Number of subjects: 163
Study 25230867 — intervention group
Group type: COMPARATOR
Intervention: HVHF and PiCCO + HVHF groups
Number of subjects: 163
Study 22412215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic device presentation (30 minutes)
Number of subjects: 95
Study 22412215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mnemonic presentation before examination)
Number of subjects: 95
Study 22412215 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey administered to both groups
Number of subjects: 95
Study 19291790 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN 9 microg/day and RBV
Number of subjects: 487
Study 19291790 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN 15 microg/day and RBV
Number of subjects: 487
Study 17690799 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-step facilitation (TSF)
Number of subjects: 148
Study 17690799 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy (ICBT)
Number of subjects: 148